-
Product Insights
Batten Disease – Drugs In Development, 2023
Global Markets Direct’s, ‘Batten Disease - Drugs In Development, 2023’, provides an overview of the Batten Disease pipeline landscape. The report provides comprehensive information on the therapeutics under development for Batten Disease, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an...
-
Product Insights
Angelman Syndrome – Drugs In Development, 2023
Global Markets Direct’s, ‘Angelman Syndrome - Drugs In Development, 2023’, provides an overview of the Angelman Syndrome pipeline landscape. The report provides comprehensive information on the therapeutics under development for Angelman Syndrome, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an...
-
Product Insights
Netherton Syndrome (Trichorrhexis Invaginata, Bamboo Hair) – Drugs In Development, 2023
Global Markets Direct’s, ‘Netherton Syndrome (Trichorrhexis Invaginata, Bamboo Hair) - Drugs In Development, 2023’, provides an overview of the Netherton Syndrome (Trichorrhexis Invaginata, Bamboo Hair) pipeline landscape. The report provides comprehensive information on the therapeutics under development for Netherton Syndrome (Trichorrhexis Invaginata, Bamboo Hair), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development...
-
Product Insights
Androgenic Alopecia – Drugs In Development, 2023
Global Markets Direct’s, ‘Androgenic Alopecia - Drugs In Development, 2023’, provides an overview of the Androgenic Alopecia pipeline landscape. The report provides comprehensive information on the therapeutics under development for Androgenic Alopecia, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an...
-
Product Insights
Spinocerebellar Ataxia (SCA) – Drugs In Development, 2023
Global Markets Direct’s, ‘Spinocerebellar Ataxia (SCA) - Drugs In Development, 2023’, provides an overview of the Spinocerebellar Ataxia (SCA) pipeline landscape. The report provides comprehensive information on the therapeutics under development for Spinocerebellar Ataxia (SCA), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the...
-
Product Insights
Alopecia – Drugs In Development, 2023
Global Markets Direct’s, ‘Alopecia - Drugs In Development, 2023’, provides an overview of the Alopecia pipeline landscape. The report provides comprehensive information on the therapeutics under development for Alopecia, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key...
-
Product Insights
Huntington Disease – Drugs In Development, 2023
Global Markets Direct’s, ‘Huntington Disease - Drugs In Development, 2023’, provides an overview of the Huntington Disease pipeline landscape. The report provides comprehensive information on the therapeutics under development for Huntington Disease, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an...
-
Company Profile
Exicure Inc – Company Profile
Exicure Inc (Exicure), formerly AuraSense Therapeutics LLC is a pharmaceutical company that discovers, develops and commercializes immunomodulatory and gene silencing drugs based on 3-dimensional spherical nucleic acid constructs. The company’s technology portfolio comprises SNA gene regulation platform and genetic analysis tools. Exicure's pipeline spans SNA based therapeutics for the treatment of psoriasis, fibrosis, diabetic ulcers, bladder cancer, and inflammation; AST008, SCN9A, CLN3, TLR9 agonist and allergan. Its SNA’s are also used as immunotherapeutic agents for the treatment of cancer and...
Add to Basket -
Product Insights
Huntington Disease Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Huntington's disease (HD) is an inherited disease that causes certain nerve cells in the brain to waste away. This is a familial disease that is passed on from parent to child through a mutation in their genes. Early symptoms of HD include uncontrolled movements, clumsiness, and balance problems. Later, HD can take away the ability to walk, talk, and swallow. The Huntington Disease pipeline market research report provides comprehensive information on the therapeutics under development for Huntington Disease (Central Nervous...
-
Product Insights
Spinocerebellar Ataxia (SCA) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Spinocerebellar ataxias (SCAs) are a group of inherited conditions that affect the brain and spinal cord causing progressive difficulty with coordination. Its symptoms include poor coordination, unsteady walking, change in speech, and difficulty swallowing. The Spinocerebellar Ataxia pipeline market research report provides comprehensive information on the therapeutics under development for Spinocerebellar Ataxia, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. The report also covers the descriptive pharmacological action...